stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) Operating cash flow
Grifols, S.A.'s operating cash flow for fiscal 2025 was $1.2B, up 21.3% from $976.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.3B. Over the past ten years it has ranged from −$11.4M (fiscal 2022) to $1.3B (fiscal 2020); the current reading is higher than 91% of that period. Operating cash flow has risen for 3 consecutive fiscal years. Grifols, S.A. ranks 15th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $1.2B | 21.34% |
| FY2024 | $976.2M | 333.07% |
| FY2023 | $225.4M | — |
| FY2022 | −$11.4M | — |
| FY2021 | $706.3M | (44.31%) |
| FY2020 | $1.3B | 99.05% |
| FY2019 | $637.2M | (26.83%) |
| FY2018 | $870.9M | (8.46%) |
| FY2017 | $951.4M | 55.40% |
| FY2016 | $612.3M | (25.77%) |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $397.8M | 51.19% |
| Jun 2026 | $263.1M | 104.35% |
| Mar 2026 | $128.7M | (72.28%) |
| Dec 2025 | $464.4M | 19.02% |
| 31 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| NVO Novo Nordisk A/S compare | $19.2B |
| GSK GSK PLC Sponsored ADR compare | $11.8B |
| BMY Bristol Myers Squibb Company compare | $10.7B |
| BIIB Biogen Inc. compare | $2.2B |
| GRFS Grifols, S.A. | $1.3B |
| OGN Organon & Co. compare | $843.0M |
| AMRN Amarin Corporation PLC compare | $37.5M |
| NSRX Nasus Pharma Ltd. compare | −$12.1M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement